Study to Assess the Safety and PK of GSK573719 and GSK573719/GW642444(VI) Combination in Healthy Subjects and Subjects With Severe Renal Impairment

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
GlaxoSmithKline
ClinicalTrials.gov Identifier:
NCT01571999
First received: April 3, 2012
Last updated: July 19, 2012
Last verified: July 2012

April 3, 2012
July 19, 2012
March 2012
June 2012   (final data collection date for primary outcome measure)
GSK573719 and vilanterol plasma pharmacokinetic parameters [ Time Frame: Treatment Period 1 and 2: pre-dose, 5 mins, 15 mins, 30 mins, 1hr, 2hrs, 4hrs, 8hrs, 12hrs, 16hrs, 24hrs ] [ Designated as safety issue: No ]
Including AUC(0-t), AUC(0-t'), Cmax, tmax, AUC(0-24), AUC(0-infinity), tlast, t1/2
GSK573719 and vilanterol plasma pharmacokinetic parameters [ Time Frame: Treatment Period 1 & 2: pre-dose, 5 mins, 15 mins, 30 mins, 1hr, 2hrs, 4hrs, 8hrs, 12hrs, 16hrs, 24hrs ] [ Designated as safety issue: No ]
Including AUC(0-t), AUC(0-t'), Cmax, tmax, AUC(0-24), AUC(0-infinity), tlast, t1/2
Complete list of historical versions of study NCT01571999 on ClinicalTrials.gov Archive Site
  • GSK573719 urine pharmacokinetic parameters [ Time Frame: Treatment Period 1 and 2: 0-4hrs, 4-8hrs, 8-12hrs, 12-24hrs ] [ Designated as safety issue: No ]
  • Vital Signs Measurements [ Time Frame: Screening (up to 21 days before dosing), Treatment Period 1 and 2: pre-dose, 5 mins, 15 mins, 30 mins, 1hr, 4hrs, 12hrs, 24hrs, Follow-up (7 to 14 days after last dose) ] [ Designated as safety issue: Yes ]
    Including systolic and diastolic blood pressure and heart rate
  • Adverse Events [ Time Frame: From administration of first dose until follow-up (7 to 14 days after last dose) ] [ Designated as safety issue: Yes ]
  • Clinical Laboratory Tests [ Time Frame: Screening (up to 21 days before dosing), Treatment Period 1 and 2: pre-dose, 24hrs, Follow-up (7 to 14 days after last dose) ] [ Designated as safety issue: Yes ]
    Including clinical chemistry, haematology and urinalysis tests
  • 12-lead ECG measurements [ Time Frame: Screening (up to 21 days before dosing), Treatment Period 1 and 2: pre-dose, 5 mins, 15 mins, 30 mins, 1hr, 4hrs, 12hrs, 24hrs, Follow-up (7 to 14 days after last dose) ] [ Designated as safety issue: Yes ]
  • GSK573719 urine pharmacokinetic parameters [ Time Frame: Treatment Period 1 & 2: 0-4hrs, 4-8hrs, 8-12hrs, 12-24hrs ] [ Designated as safety issue: No ]
  • Vital Signs Measurements [ Time Frame: Screening, Treatment Period 1 & 2: pre-dose, 5 mins, 15 mins, 30 mins, 1hr, 4hrs, 12hrs, 24hrs, Follow-up ] [ Designated as safety issue: Yes ]
    Including systolic and diastolic blood pressure and heart rate
  • Adverse Events [ Time Frame: From administration of first dose until follow-up ] [ Designated as safety issue: Yes ]
  • Clinical Laboratory Tests [ Time Frame: Screening, Treatment Period 1 & 2: pre-dose, 24hrs, Follow-up ] [ Designated as safety issue: Yes ]
    Including clinical chemistry, haematology and urinalysis tests
  • 12-lead ECG measurements [ Time Frame: Screening, Treatment Period 1 & 2: pre-dose, 5 mins, 15 mins, 30 mins, 1hr, 4hrs, 12hrs, 24hrs, Follow-up ] [ Designated as safety issue: Yes ]
Not Provided
Not Provided
 
Study to Assess the Safety and PK of GSK573719 and GSK573719/GW642444(VI) Combination in Healthy Subjects and Subjects With Severe Renal Impairment
A Single-blind, Non-randomized Pharmacokinetic and Safety Study of Single Dose of GSK573719 and GSK573719 + GW642444 Combination in Healthy Subjects and in Subjects With Severe Renal Impairment

This study will assess the safety and pharmacokinetics of inhaled GSK573719 and GSK573719/vilanterol combination in healthy subjects and in subjects with severe renal impairment. The results of the study will provide guidance on the use of this product in subjects with severe renal impairment.

GSK573719 monotherapy and GSK573719/vilanterol combination are currently under development for the treatment of COPD. This study will assess the pharmacokinetics and safety of inhaled GSK573719 and GSK573719/vilanterol (VI) in healthy subjects and in subjects with severe renal impairment. Nine subjects with severe renal impairment (as defined by a Clcr<30mL/min) will be recruited along with healthy control subjects (as defined by a Clcr>80mL/min matched to the severe renal impairment subjects based on gender, ethnicity, body mass index (±15%) and age (±5 years)). The results from this study will provide guidance on the use of GSK573719 and GSK573719/VI in severe renally impaired patients.

Interventional
Phase 1
Allocation: Non-Randomized
Endpoint Classification: Pharmacokinetics Study
Intervention Model: Crossover Assignment
Masking: Single Blind (Subject)
Primary Purpose: Basic Science
Pulmonary Disease, Chronic Obstructive
  • Drug: Inhaled GSK573719
    All subjects will receive a single dose of GSK573719 (125mcg) in treatment period 1
  • Drug: Inhaled GSK573719/vilanterol
    All subjects will receive a single dose of GSK573719 (125mcg)/vilanterol (25mcg) in treatment period 2
  • Experimental: Severe renally impaired subjects
    Approximately 9 subjects will complete each treatment arm
    Interventions:
    • Drug: Inhaled GSK573719
    • Drug: Inhaled GSK573719/vilanterol
  • Experimental: Matched healthy volunteers
    Matched to the severe renal impairment subjects based on gender, ethnicity, body mass index (±15%) and age (±5 years). Approximately 9 subjects will complete each treatment arm
    Interventions:
    • Drug: Inhaled GSK573719
    • Drug: Inhaled GSK573719/vilanterol
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
17
June 2012
June 2012   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Male or female between 18 and 70 years of age inclusive, at the time of signing the informed consent.
  • A female subject is eligible to participate if she is of:

Non-childbearing potential defined as pre-menopausal females with a documented tubal ligation or hysterectomy; or postmenopausal defined as 12 months of spontaneous amenorrhea or, child-bearing potential and is abstinent or agrees to use one of the contraception methods listed in the protocol for an appropriate period of time prior to the start of dosing to sufficiently minimize the risk of pregnancy at that point. Female subjects must agree to use contraception until follow-up.

  • Body weight greater than or equal to 45 kg and body mass index (BMI) within the range 18 - 33 kg/m2 (inclusive)
  • Single QTcF less than 450 msec; or QTc less than 480 msec in subjects with Bundle Branch Block.

Healthy Subjects:

  • Healthy as determined by a responsible and experienced physician, based on a medical evaluation including medical history, physical examination, laboratory tests and cardiac monitoring
  • Alanine aminotransferase (ALT), alkaline phosphatase and bilirubin less than or equal to 1.5x Upper Limit of Normal (ULN)
  • Creatinine clearance greater than 80mL/min calculated by the Cockcroft-Gault equation using serum creatinine

Renally Impaired subjects:

  • ALT less than 2xULN; alkaline phosphatase and bilirubin less than or equal to 1.5xULN
  • Creatinine clearance less than 30mL/min calculated by the Cockcroft-Gault equation using serum creatinine.
  • Subjects with renal insufficiency must have stable renal function defined as less than or equal to a 25% difference in creatinine clearance assessed on two occasions. Renal function will be based on estimated creatinine clearance (CLcr) calculated by the Cockcroft-Gault equation using serum creatinine obtained on two occasions separated by at least 4 weeks within the last 3 months

Exclusion Criteria:

  • Suffered a lower respiratory tract infection in the 4 weeks before the screening visit
  • A supine mean heart rate outside the range 40-90 beats per minute (BPM) at screening
  • A positive pre-study drug/alcohol screen
  • A positive test for HIV antibody
  • Current or chronic history of liver disease, including documented cirrhosis or a history consistent with a diagnosis of cirrhosis, or known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones)
  • The subject has participated in a clinical trial and has received an investigational product within the following time period prior to the first dosing day in the current study: 30 days, 5 half-lives or twice the duration of the biological effect of the investigational product (whichever is longer)
  • Exposure to more than four new chemical entities within 12 months prior to the first dosing day
  • Use of nephrotoxic medications 4 weeks before dosing
  • Where participation in the study would result in donation of blood or blood products in excess of 500 mL within a 56 day period
  • Pregnant females as determined by positive serum or urine hCG test at screening or prior to dosing.
  • Lactating females
  • The subject has been treated for or diagnosed with depression within six months of screening or has a history of significant psychiatric illness
  • Unwillingness or inability to follow the procedures outlined in the protocol
  • Subject is mentally or legally incapacitated
  • Subjects with smoking history of greater than 10 cigarettes per day or regular use of tobacco- or nicotine-containing products, within 6 months prior to screening
  • History of sensitivity to any of the study medications, or components thereof or a history of drug or other allergy that, in the opinion of the investigator or GSK Medical Monitor, contraindicates their participation.
  • Unable to refrain from consumption of red wine, seville oranges, grapefruit or grapefruit juice and/or pummelos, exotic citrus fruits, grapefruit hybrids or fruit juices from 7 days prior to the first dose of study medication.

Healthy Subjects:

  • Subjects with any predisposing condition that might interfere with the absorption, distribution, metabolism or excretion of drugs or any previous gastrointestinal (GI) surgery which the investigator considers sufficiently significant to interfere with the conduct, completion, or results of this trial or constitutes an unacceptable risk to the subject.
  • Urinary tract or bladder infection within 4 weeks of the first scheduled administration of study drug.
  • A positive pre-study Hepatitis B surface antigen or positive Hepatitis C antibody result within 3 months of screening.
  • Current or chronic history of liver disease, or known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones)
  • History of regular alcohol consumption within 6 months of the study defined as an average weekly intake of greater than 21 units for males or greater than 14 units for females.
  • Unable to refrain from the use of prescription or non-prescription drugs, including vitamins, herbal and dietary supplements (including St John's Wort) within 7 days (or 14 days if the drug is a potential enzyme inducer) or 5 half-lives (whichever is longer) prior to the first dose of study medication, unless in the opinion of the Investigator and GSK Medical Monitor the medication will not interfere with the study procedures or compromise subject safety.

Renally Impaired Subjects:

  • Life expectancy less than 3 months
  • Hemoglobin less than 8.5 g/dL (for sites in Hungary), or hemoglobin less than 11.0g/dL (for sites in the Czech Republic)
  • Subjects on hemodialysis treatment
  • Subjects who, within the past six months, have had a history of significant drug abuse or alcohol abuse
  • Subjects who need to take any concomitant medication, either prescribed or overthe- counter, which may in the opinion of the Investigator, interfere in any way with the study procedure or be a safety concern. In particular subjects taking medications that significantly inhibit P450 CYP3A4 (e.g. ketaconazole) must not be included in this study
  • If in the opinion of an examining physician an unstable cardiovascular, pulmonary or hepatic condition is present, or any other medical condition which the investigator considers sufficiently serious to interfere with the conduct, completion, or results of this trial or constitutes an unacceptable risk to the subject
Both
18 Years to 70 Years
Yes
Contact information is only displayed when the study is recruiting subjects
Czech Republic,   Hungary
 
NCT01571999
114636
No
GlaxoSmithKline
GlaxoSmithKline
Not Provided
Study Director: GSK Clinical Trials GlaxoSmithKline
GlaxoSmithKline
July 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP